Collaborative work continues to be performed globally to further research and clinical developments in myositis. Serological, image-based and histopathological investigations now allow for a more timely diagnosis, accurately clinical phenotyping and can help to prevent misdiagnosis of disease. Recommended and cutting edge modalities of investigations will be discussed via brief case presentations. The classification of myositis is somewhat more refined than it has been hitherto; great efforts have been made to develop new criteria which will be summarised. The evidence base and consensus for treatment in myositis remains suboptimal, although the use of biologics is slowly increasing; pharma are now conducting multinational trials across the idiopathic inflammatory myopathy spectrum. The development and utility of myositis registries will also be outlined.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.6109